Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) Given Consensus Rating of "Moderate Buy" by Brokerages

Shares of Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB - Get Free Report) have received an average recommendation of "Moderate Buy" from the eight analysts that are currently covering the stock, Marketbeat reports. One analyst has rated the stock with a sell rating, one has assigned a hold rating and six have issued a buy rating on the company. The average 1-year price objective among brokers that have updated their coverage on the stock in the last year is $56.35.

A number of equities analysts have issued reports on the company. Leerink Partners set a $75.00 price target on Zai Lab and gave the company an "outperform" rating in a research note on Monday, June 30th. Jefferies Financial Group began coverage on Zai Lab in a research note on Monday, August 25th. They set a "buy" rating and a $52.00 target price for the company. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Zai Lab in a research note on Saturday, September 27th. Citigroup reaffirmed a "buy" rating and set a $69.00 target price (up previously from $66.00) on shares of Zai Lab in a research note on Monday, August 11th. Finally, Wall Street Zen lowered shares of Zai Lab from a "buy" rating to a "hold" rating in a research report on Friday, June 27th.

Zai Lab Stock Down 1.3%

Shares of ZLAB opened at $32.89 on Wednesday. The firm has a 50-day moving average price of $33.74 and a 200 day moving average price of $33.65. The firm has a market capitalization of $3.68 billion, a PE ratio of -16.12 and a beta of 1.08. Zai Lab has a 52-week low of $23.70 and a 52-week high of $44.34.

Zai Lab (NASDAQ:ZLAB - Get Free Report) last announced its earnings results on Thursday, August 7th. The company reported ($0.37) earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of ($0.37). The firm had revenue of $109.98 million during the quarter, compared to analyst estimates of $125.66 million. Zai Lab had a negative net margin of 49.68% and a negative return on equity of 27.32%. Zai Lab has set its FY 2025 guidance at EPS. On average, equities analysts expect that Zai Lab will post -2.58 EPS for the current year.

Insider Buying and Selling at Zai Lab

In related news, CFO Yajing Chen sold 1,438 shares of the stock in a transaction on Friday, August 15th. The stock was sold at an average price of $35.42, for a total value of $50,933.96. Following the completion of the transaction, the chief financial officer owned 16,720 shares in the company, valued at $592,222.40. This trade represents a 7.92% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider Joshua L. Smiley purchased 10,000 shares of the firm's stock in a transaction that occurred on Wednesday, September 10th. The stock was bought at an average price of $28.91 per share, with a total value of $289,100.00. Following the transaction, the insider directly owned 86,604 shares in the company, valued at $2,503,721.64. This trade represents a 13.05% increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last three months, insiders have sold 161,562 shares of company stock valued at $5,650,256. 4.96% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Acadian Asset Management LLC acquired a new position in shares of Zai Lab in the first quarter worth about $1,073,000. MPM Bioimpact LLC boosted its stake in Zai Lab by 4.2% in the 1st quarter. MPM Bioimpact LLC now owns 833,659 shares of the company's stock worth $30,128,000 after purchasing an additional 33,659 shares during the period. Frazier Life Sciences Management L.P. acquired a new position in Zai Lab in the 1st quarter worth approximately $12,649,000. Cubist Systematic Strategies LLC boosted its stake in Zai Lab by 29.0% in the 1st quarter. Cubist Systematic Strategies LLC now owns 93,645 shares of the company's stock worth $3,384,000 after purchasing an additional 21,026 shares during the period. Finally, Royal Bank of Canada boosted its position in shares of Zai Lab by 214.3% in the first quarter. Royal Bank of Canada now owns 13,771 shares of the company's stock worth $498,000 after buying an additional 9,390 shares during the period. 41.65% of the stock is currently owned by institutional investors and hedge funds.

Zai Lab Company Profile

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.